This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2030 Remove Compounding Remove Immunization Related Topics
Documentation Communication Vaccines More Related Topics >
article thumbnail

Healthier Together and philanthropic ventures in tropical disease

European Pharmaceutical Review

JUNE 27, 2022

The Kigali Summit on Malaria and NTDs , hosted by His Excellency (HE) Paul Kagame, President of the Republic of Rwanda, on Thursday 23 June 2022, gathered world leaders to commit to ending these devastating diseases by the end of 2030. Did you know, 1.7 LXE408 is currently entering Phase II clinical development.

Vaccines 92
Vaccines Communication Documentation Compounding 92
article thumbnail

Cell Therapy Pipeline Update: Talaris Therapeutics Announces Initiation of Phase 3 Clinical Trial

Roots Analysis

FEBRUARY 28, 2024

This therapy induces or restores patients’ immune tolerance by establishing stable donor chimerism in the transplant recipient without the need for life-long immunosuppression. The stem cell manufacturing market for CMO is expected to grow at compounded annual growth rate (CAGR) of 18% during the forecast period 2019 – 2030.

Compounding 40
Compounding Immunization 40
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 18,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024